Vulvar squamous cell carcinoma has an 8–16% TP53 mutation prevalence in HPV-positive tumors versus 30–76% prevalence in HPV-negative tumors, and vulvar intraepithelial neoplasia (VIN) precancerous lesions have a 3% TP53 mutation prevalence in HPV-positive and 21% prevalence in HPV-negative lesions [73,74]. Here, TP53 is linked to vulvar squamous cell carcinoma.